MOTS-c: The Definitive Guide

What is MOTS-c?

MOTS-c is a small peptide, a chain of 16 amino acids, that human cells make from a gene inside their mitochondria, the tiny structures that produce most of a cell's energy. In mice it improved blood-sugar control, resisted weight gain on a fatty diet and helped older animals run farther. People buy lab-made MOTS-c hoping for more energy, better endurance and healthier aging. It is not an approved medicine, and no published study has given it to people. [1], [2], [3]

The name is short for “mitochondrial open reading frame of the 12S rRNA type-c”. In plain terms, researchers found a short stretch of instructions hidden inside a mitochondrial gene called MT-RNR1, whose main job is to build part of the mitochondria's own protein-making machinery. A team at the University of Southern California described the peptide in 2015. It belongs to a small family called mitochondrial-derived peptides, which also includes humanin. [1], [4]

Its sequence is MRWQEMGYIFYPRKLR, its formula C101H152N28O22S2 and its weight about 2,175 g/mol. It is sold in two forms, the free base and the acetate, usually as freeze-dried powder in 5 or 10 mg vials labelled “research use only”. Mouse and rat versions of the peptide have different sequences, and most animal papers do not say which one they used. [3], [1], [5]

MOTS-c and CB4211 are different molecules. CB4211 is a modified analogue that the company CohBar developed from MOTS-c and tested in people. Its results are often quoted as if they were MOTS-c results, and they are not. [4], [6]

The key word for MOTS-c is investigational, and it is an unusual case even among research peptides. FDA's 2026 review found no clinical studies and no human exposure data “via any route of administration”. What exists in people are measurements of the MOTS-c the body already makes, one company trial of the analogue, and a large number of personal accounts. [3]

Typical MOTS-c Protocols

The most common pattern in the reviewed dosing pages is 5–10 mg per subcutaneous injection, two or three times a week, for about 4–8 weeks, and 5 mg three times a week (15 mg a week) is the starting point named most often. Fourteen of the 29 pages we compared belong to this “5–10 mg a few times a week” family. [10], [11], [12], [13], [14], [15], [16]

Titration Changing the amount in steps

Sources start in opposite places. The daily pages start at 200 mcg and add 200 mcg every two weeks. One physician's page starts everyone at 5 mg three times a week and may move to 5–10 mg three to five times a week from week 3; a clinic page starts at 2.5–5 mg two or three times a week for 2–4 weeks; a seller's page uses 5 mg a week split into three injections for weeks 1–3, then 10 mg a week. [7], [14], [17], [18]

Breaks and cycles

Most pages describe 4–12 weeks of use, then 2–8 weeks off: for example 4 weeks on and 4 off, 8–10 weeks on and 4–5 off, or 12 weeks on and 4–8 off. A clinic schedule of four 5 mg injections five days apart is followed by at least four months off. No study has tested whether breaks are needed. [9], [8], [15], [19]

Timing

Pages usually say morning, fasted, or 30–60 minutes before exercise, and one says never after 2 PM because of sleep. No study has compared times of day. [9], [14], [8]

Read the units: mcg means micrograms; 1 mg equals 1,000 mcg. The dose is the amount in one injection and the weekly total is everything injected in a week. The two families above differ more than tenfold: 200 mcg a day adds up to 1.4 mg a week, while 5 mg three times a week adds up to 15 mg. A vial size (5, 10 or 40 mg) is a product amount, not a dose. [7], [9], [3]

Each row is a complete schedule from one source, so its amount and duration belong together. Low, mid and high are alternatives, not steps to move through. These schedules come from protocol websites rather than clinical trials; none cites a human study of MOTS-c, and the cited references give the full details. [3], [7]

Before relying on any row: no amount in this table has been tested for safety in people. FDA found no human exposure data, no animal toxicity studies and no measurement of how long MOTS-c stays in the body. [3] The only people ever dosed received the analogue CB4211, and 79% of them had injection-site reactions, compared with 33% on placebo. [20], [21] Online, itchy welts and lumps are the most common complaint, and some people describe whole-body allergic-type reactions, often after restarting following a break. Swelling of the lips, tongue or throat, trouble breathing or faintness after an injection needs emergency care. [22], [23], [24] MOTS-c lowered blood sugar in mice and CB4211 lowered it in people, so anyone on insulin or a sulfonylurea has extra reason for caution. [1], [21] FDA found no published testing of MOTS-c products for impurities, bacterial toxins or microbial contamination, and a mixing mistake changes every dose, so work out syringe units with the reconstitution calculator rather than copying them. [3] It has not been studied in pregnancy, breastfeeding or anyone under 18, and it is banned in sport at all times. [3], [25] Full risks ↓

In public forums, the single amounts people mention most often are 5, 2, 1 and 3 mg per injection. In community education groups, members most often describe 1–1.5 mg a day (sometimes five days on and two off) or 3.3–5 mg three times a week, while the most cautious course there treats anything from 5 mg per injection upward as high risk for reactions. These describe practice, not tested doses. [26], [27]

Where protocols differ: daily versus weekly amounts, frequency, breaks and nasal sprays ↓

What is MOTS-c commonly used for?

People usually look into MOTS-c for one of a few reasons: low energy, especially while on a GLP-1 weight-loss medicine; a wish to run, cycle or train harder; weight and blood-sugar control; or healthier aging. It is often called an “exercise mimetic”, a substance that copies some effects of exercise. That label comes from mouse studies. [34], [26], [2]

The withdrawn US compounding nomination listed insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism, and longevity. FDA found no clinical studies of MOTS-c for any of them. The sections below describe what people hope for and what has actually been measured. [3]

Energy and fatigue

This is the most common reason in public discussions. People describe hoping for steady, non-jittery energy, no afternoon slump, or relief from the tiredness that can come with GLP-1-based medicines such as tirzepatide or retatrutide, taken at the same time. [35], [34], [36]

Reports go both ways, sometimes in the same person. Some describe clean energy within days; others describe no change, or fatigue and an afternoon “crash”, especially in the first weeks. Almost everyone reporting was also taking other compounds, which makes MOTS-c's own contribution impossible to separate. No human study has measured energy or fatigue after MOTS-c. The experience section follows these accounts. [27], [35], [26]

Endurance and exercise performance

The mouse results behind this use are real but specific. Old mice given daily injections for two weeks ran about twice as long on a treadmill, and a single dose 10 minutes before exercise increased running time by 12% in another mouse study. In young men, the body's own MOTS-c rose about 12-fold in muscle after a hard cycling session. None of this shows that injecting MOTS-c improves performance in people. [2], [37]

Community accounts describe faster run and swim times and easier cardio, often while starting a new training plan, losing weight or taking other compounds. [38], [26]

Weight, blood sugar and insulin sensitivity

The founding 2015 paper found that mice on a high-fat diet gained less weight and had less fatty liver with daily MOTS-c, and that it improved how muscle responded to insulin (insulin sensitivity). Later mouse studies reported similar blood-sugar effects. [1], [39]

In people, the only data come from CB4211, the analogue: over four weeks in 20 adults with obesity and fatty liver, blood sugar and a liver enzyme fell more than on placebo, but liver fat fell by the same amount in both groups. Weight reports in forums almost always involve a GLP-1 medicine as well, and several people describe more hunger, not less, after adding MOTS-c. [21], [40], [41]

Healthy aging and longevity

MOTS-c is sold as a longevity peptide largely because of one 2021 mouse study. Very old mice injected three times a week had better grip strength and walking, but the lifespan result was not statistically significant: median life was about 6% longer (970 versus 912 days) with a probability value of 0.23, and the authors said larger studies were needed. Descriptions of a 10% longer life, including testimony at FDA's advisory meeting, overstate it. See the aging studies. [2], [6]

Muscle and bone

Mouse studies report less muscle loss during leg immobilization and during cancer-related wasting, and less bone loss after the ovaries were removed, a model of post-menopausal osteoporosis. In human muscle cells grown in a dish, MOTS-c prevented the shrinkage caused by the steroid dexamethasone. These are single models, mostly from a few laboratories, with no data from people given MOTS-c. [42], [43], [44], [45]

Other uses you may come across

Claims about the immune system, infections, heart health, brain fog, chronic fatigue and long COVID go beyond the evidence. Some rest on real laboratory findings: in 2026 researchers showed that MOTS-c can attack bacteria in a dish, and a mouse study linked it to better survival from a resistant staph infection. A 2026 heart-rhythm study measured MOTS-c in people with atrial fibrillation and tested the peptide only in mice. Others are extrapolations from animal models or from people's own accounts. [46], [47], [48], [36]

See what human studies show or explore the supporting mouse and cell research.

Where do MOTS-c protocols differ?

The amounts are harder to summarize for MOTS-c than for most peptides, because two families of pages disagree more than tenfold, and the most popular schedules were not derived from any study. Here is what each difference means when reading a protocol.

Is the number per injection, per day or per week?

5 mg three times a week is 15 mg a week, while 200 mcg a day is 1.4 mg a week. Some pages give a weekly total, others an amount per injection, and a few mix the two: one seller's page labels a 5 mg weekly total split three ways (about 1.6 mg each time) in a way that confuses the two. Check which number you are reading before comparing. [9], [7], [18]

Micrograms every day or milligrams a few times a week?

These are two separate traditions. The microgram family (200–1,000 mcg a day) copies one table from page to page. The milligram family (5–10 mg two or three times a week) is more common on clinic and calculator pages. One weekly-total page argues that splitting 10 mg into two or three injections keeps the signal steadier than one large dose, while others use a single larger injection every five days; neither argument has been tested in people. [28], [31], [10], [8], [19]

Doserly

Website schedules differ more than tenfold

Website protocols, not clinical evidence

Weekly total, log scale

Daily micrograms

200 mcg a day, rising by 200 mcg every 2 weeks to 1,000 mcg8–12 weeks · Same table on at least 7 other pages1.4 → 7 mg a week

Every five days

5 mg every 5 days, 4 injections (20-day block)20 days, then at least 4 months off · About 7 mg a week during the block≈7 mg a week

Weekly total

10 mg a week as 3 × 3.33 mg or 2 × 5 mg8–10 weeks, then 4–5 off10 mg a week

5–10 mg a few times a week

5 mg 3×/week (beginner) to 10 mg 5×/week (aggressive)4 weeks on, 4 off · The largest family of pages15–50 mg a week

CB4211 trial (analogue, not MOTS-c)

25 mg once daily for 4 weeks Different molecule175 mg a week

Nasal spray products (125 mcg per spray) are not comparable: absorption is unmeasured.

None of these schedules came from a human study of MOTS-c. The only dose ever given to people was of a different molecule.

How often: daily, three times a week or every five days?

All three appear. Daily pages use one injection a day. The milligram pages use two or three a week, and some go up to five times a week or daily at 5–10 mg. Two clinic documents use 5 mg every five days for four injections, a 20-day block. One clinic page says continuous use risks blunting the effect, which is its reason for a four-month rest; no study has tested that. [9], [11], [19], [33]

Do sources start low, or start at 5 mg?

Both. The daily family starts at 200 mcg and steps up slowly. Several milligram pages start at 5 mg, and one physician's page begins everyone there before raising the amount. A clinic page starts lower, at 2.5–5 mg, and increases after 2–4 weeks. One page tells readers to hold 5 mg before considering an increase. There is no evidence that failing to notice anything at a lower amount means a higher one will work. [7], [14], [17], [10]

How long, and what happens between cycles?

Course lengths run from 20 days to 12 weeks, with some pages allowing up to 16 weeks. Breaks run from one or two weeks to at least four months, and some pages suggest two or three cycles a year. None of these break lengths comes from a study; they are conventions. [19], [32], [15], [49]

Where do the sources disagree most?

• Amount per injection: from 200 mcg to 15 mg on the pages we compared, a 75-fold range. A higher listed amount is not a verified safe ceiling. [7], [50]
• Frequency: daily, five days a week, three times a week, twice a week, every five days or once a week at 10 mg. [51], [19]
• What the numbers are based on: several pages say their amounts come from “early published data” or a “Phase I” trial of MOTS-c up to 10 mg. The only human trial was of CB4211, a different molecule, at 25 mg a day. [9], [17], [52], [21]
• Half-life claims: pages give figures from 1–2 hours to 4 hours, and none cites a measurement. [9], [50], [3]

Why do some pages give a dose per kilogram?

Some pages start from mouse doses (0.5 to 15 mg per kilogram a day, injected into the belly cavity) and scale them to a person, arriving at figures such as 0.05–0.15 mg per kilogram per injection. That arithmetic produces a number; it is not a dose tested in people, and it ignores differences in route, product and how the body handles the peptide. [17], [1], [2]

Other routes: nasal sprays

One seller offers a nasal spray delivering 125 mcg per spray, used as two to six sprays once or twice a day for 8–12 weeks. How much of a sprayed peptide reaches the blood has not been measured for MOTS-c, so these amounts cannot be compared with injected ones. [32], [3]

How do milligrams convert to syringe units?

Many people meet “units” on an insulin syringe. A U-100 syringe has 100 units per millilitre, so units measure volume, not an amount of MOTS-c. How much MOTS-c each unit holds depends on how much liquid was added to the vial.

For example, a 10 mg vial mixed with 2 mL gives 5 mg per mL, or 50 mcg per unit, so 1 mg would be 20 units and 5 mg would be 100 units, a full 1 mL syringe. The same 1 mg is a different number of units in a vial mixed differently, which is why a number of units copied from someone else's protocol can be wrong. Doserly's reconstitution calculator works this out for any vial and shows each step. [9]

Concentration has another limit. FDA's review lists the acetate form's solubility in water at 6.25 mg per mL, and at the advisory meeting the US Pharmacopeia's representative said a 10 mg per mL injection would be hard to formulate. Some protocol pages mix vials at 10–13 mg per mL, above that figure. [3], [6], [8], [7]

What happens when you stop MOTS-c?

This has not been studied. No study in people or animals has looked at what happens after MOTS-c is stopped, whether effects wear off, or whether anything rebounds (withdrawal or rebound). That is an absence of data, not proof that nothing happens. [3]

• How long mouse effects lasted. The mouse studies measured animals during or just after treatment; they did not follow what happened in the weeks after injections ended. [1], [2]
• Community accounts point both ways. Some people describe energy benefits fading over weeks or months while still injecting; one person said raised heart rate and blood pressure returned to normal two days after stopping; another described nervousness and sensitivity to stimulants that continued after stopping. [60], [27], [61]
• Restarting after a break is the bigger reported issue. Several people describe injection-site or whole-body reactions that appeared only when they restarted after a break. See the risks section. [23], [24]

Protocol pages that recommend a break describe it as a way to keep the body responsive, not as a response to known withdrawal effects, and neither idea has been tested. [32], [19] In community education groups, one educator describes a 4-week taper to avoid a “crash” and calls it hypothetical.

Is MOTS-c injected, and does the form matter?

Protocol websites describe subcutaneous injection (into the fatty layer under the skin), and some also mention intramuscular injection (into a muscle). Most animal studies used a different route: intraperitoneal injection, into the belly cavity, which is not used in people. Some used slow-release pumps, injections into a vein (intravenous) or injections into the spinal fluid or brain. These are distinct exposures, not interchangeable versions of one experiment. [10], [1], [62], [63], [64], [65]

No study has measured how much MOTS-c reaches the blood after a subcutaneous injection in any species. The “80% bioavailability” figure seen on some pages has no published source. Bioavailability describes how much of a dose reaches the circulation; for MOTS-c it is simply unknown. [3], [52]

Can MOTS-c be taken by mouth or reach the brain?

Swallowed natural MOTS-c did not improve colitis in mice, while a modified version designed to survive digestion did, which suggests the natural peptide is broken down in the gut. Injected natural MOTS-c also did not reach the brain well in mice; researchers had to attach a carrier to get it there. Claims about brain fog and memory rest on those modified versions. [66], [67]

Free base, acetate or CB4211?

The free base and the acetate are the same peptide with or without a paired acetate molecule, and they are the two forms FDA evaluated. FDA noted that sellers name them inconsistently and that the same registry number is used for both. CB4211 is not a form of MOTS-c but a modified molecule, and its dose and side effects cannot be carried over. [3], [6]

How long does MOTS-c last in the body?

Nobody knows. FDA found no study measuring how the body absorbs, moves and removes MOTS-c (pharmacokinetics) in any species. The only related experiment added MOTS-c to human blood in a test tube: within 15 minutes it had been cut into shorter fragments. A test tube is not a body, so this does not give a half-life either. [3], [68]

Half-life is the time it takes for a measured level in the blood to fall by half. Figures of 1–2 hours, 2–3 hours or 4 hours appear on dosing pages and in community discussions, and none cites a measurement. [9], [12], [50] In one mouse study, a naturally occurring variant of MOTS-c was cleared 2.6 times more slowly than the usual form, which shows that clearance was measured in that study but does not give a human figure. [62]

In young men, the body's own MOTS-c rose in the blood during and after exercise and was back to its starting level within four hours. That describes natural release, not an injected dose. [2]

How should MOTS-c be stored, and how long does it last?

No stability study of a MOTS-c product has been published, so storage advice comes from suppliers and protocol pages, not a tested medicine label. [3]

• Powder, before mixing. FDA's review cites reports that freeze-dried MOTS-c powder is stable at −20 °C, kept dry and protected from light in a tightly closed container. [3]
• After mixing. Once the powder is mixed with liquid (reconstituted), the supplier guidance FDA quotes says to keep it at 4 °C for 2–7 days, or below −18 °C for later use. Protocol pages instead give 7 days, 3–4 weeks, 28 days or about 30 days in the fridge, and one says 25% of activity is lost after 24 hours, without a source. [3], [7], [11], [14], [15]
• Heat, light and freezing. No published study has tested these for MOTS-c in a vial, so every duration above is a claim, not a tested expiry date. Forum discussions dispute rapid breakdown claims in both directions. [53], [69]

Storage is not only about strength. FDA notes that peptides can break down or clump together (aggregation), and that clumps and impurities can make an injected product more likely to trigger an immune reaction. This guide does not cover mixing or injection technique; the Academy note below covers practical handling. [3]

What do we actually know about MOTS-c in people?

Very little, and almost none of it involves giving MOTS-c to anyone. Human research on MOTS-c falls into three groups: one company trial of a modified version, one registry entry of doubtful authenticity, and dozens of studies that measure the MOTS-c people's bodies already make (endogenous MOTS-c). Each answers a different question. [3], [70]

Has MOTS-c ever been tested as a treatment in people?

No. FDA's July 2026 review states that neither the nomination nor FDA's own searches identified “any clinical studies or human exposure data for MOTS-c via any route of administration”. None of the 262 PubMed records for MOTS-c and its other spellings describes giving the natural peptide to a person. [3], [71]

That makes MOTS-c different from peptides with at least a few small human reports. Every statement about how people respond to injected MOTS-c comes from personal accounts, not from a study.

Doserly

What has actually been tested

Counts of published research, September 2026

Cells

22cell studiesConcentrations in a dish, for example 10 µM

Animals

79papers giving MOTS-c to animals125 dosing regimens; mostly mice, mostly injections into the belly cavity

People

0published studies gave MOTS-c itself to peopleFDA found no clinical studies or human exposure data by any route

People

1trial gave the analogue CB421188 enrolled; in the Phase 1b stage, 25 mg a day for 4 weeks in 11 people with fatty liver, 9 on placebo

People

67studies measured the body's own MOTS-cExercise, age, obesity and disease; the blood tests disagree with each other

Counts from our classification of all 262 PubMed records for MOTS-c (the rest are 75 reviews, 9 animal measurement studies and a few others) and ClinicalTrials.gov searches. A 2026 registry entry for a Phase 2a MOTS-c trial is not counted because its authenticity is in doubt.

Plenty of laboratory research, but no published study has given MOTS-c itself to a person.

What did the CB4211 trial find?

CB4211 was CohBar's modified version of MOTS-c, described by the company as a “novel and improved analog”. It is the only MOTS-c-related molecule ever given to people in a registered trial. [4], [55]

What happened next matters. In its 2022 annual report the company said it did not believe the stage 1b formulation was “suitable for further development” and that efforts to improve it had not succeeded. In November 2023 it announced plans to liquidate and dissolve, and Nasdaq moved to delist its shares. At FDA's 2026 advisory meeting, an FDA reviewer confirmed that CB4211 is considered a different substance from MOTS-c. [4], [72], [6]

Is there a Phase 2 MOTS-c trial?

A 2026 ClinicalTrials.gov entry describes a Phase 2a trial of daily MOTS-c injections for 12 weeks in 120 adults with prediabetes and overweight, listed as recruiting, with the amount per injection left blank. The same sponsor filed other entries at the same time, including one that describes itself as a “fictional study” and one titled “(Mock Study)”, and two of its records reuse another drug company's protocol codes. We found no independent confirmation that the trial exists, so this guide does not treat it as evidence. [56], [57], [58], [59]

What do studies of the body's own MOTS-c show?

These are observational studies: researchers measure MOTS-c in blood or muscle and compare groups. They can show links, not cause and effect, and none of them tests whether taking MOTS-c helps.

• Exercise raises it, briefly. In 10 sedentary young men, MOTS-c in muscle rose about 12-fold after cycling, and blood levels rose about 1.5-fold, returning to normal within four hours. A randomized study of 30 people found only a trend toward higher levels after endurance exercise, and a 2026 study found no net release from working muscle into the blood. Eight weeks of training did not change resting levels in women with or without polycystic ovary syndrome. [2], [73], [74], [75]
• Age is not a simple decline. Older men had lower blood levels than young men but about 1.5 times more MOTS-c in their muscle. [76]
• Obesity studies disagree. One small study found the same levels in lean and obese adults; a 2026 study found higher levels in obesity that did not change after weight-loss surgery; a study of children found lower levels in obesity. [77], [78], [79]
• Sleep apnea. Two studies found lower blood MOTS-c in people with obstructive sleep apnea, falling with severity. [80], [81]
• A common gene variant. A variant called K14Q changes one amino acid in MOTS-c; the peptide's discoverer told FDA's advisory committee that about 8% of Japanese people carry it. In large Japanese studies, men with it had a higher rate of type 2 diabetes, and the variant was linked to muscle fiber type; in mice, the variant peptide was less active. [62], [82], [6]

Why do the numbers disagree so much?

Because the tests disagree. A doping-control laboratory found that a commercial antibody test (immunoassay) reported 45.9–218.5 ng/mL in 20 healthy people, levels its more specific mass-spectrometry test could not confirm. Other studies report averages of about 0.2–0.5 ng/mL, hundreds of times lower. There is no reliable “normal range” for MOTS-c, and a single result from a private lab cannot tell anyone whether their level is low. [68], [77], [78]

What would a useful change look like?

Energy and endurance are the outcomes people care about most, and both are easy to misjudge. A better run can come from training, weight loss, sleep, caffeine or a new medicine. If you and a clinician decide to try something, a written record of what changed, when, and alongside what else, is the only way to see a pattern in your own data.

How might MOTS-c work?

MOTS-c is best understood as a stress signal. When cells run short of fuel, the experiments suggest, MOTS-c helps switch them into an energy-saving, fuel-burning mode. The details below come from cell and mouse studies. FDA's 2026 review says the “molecular target(s)” behind its effects remain unknown, although a 2024 study reported that it binds an enzyme called CK2 (below). [3]

A signal through AMPK, the cell's fuel gauge

In the founding study, MOTS-c in cells slowed a pathway called the folate cycle, which let a molecule called AICAR build up. AICAR switches on AMPK, an enzyme that senses low energy and tells the cell to take up more sugar and burn more fat. In cells, blocking AMPK only partly reduced MOTS-c's effects. That is why MOTS-c is compared with exercise, which also switches on AMPK. [1]

One caution follows from this. People sometimes say MOTS-c “uses up folate”, and advise taking methylfolate. A later mouse study measured the folate cycle after MOTS-c injections and found no change, and no study has shown folate depletion in animals or people. [39]

Moving into the nucleus under stress

In cells under stress, MOTS-c moved from the fluid of the cell into the nucleus within about 30 minutes, where it helped switch on protective genes, including antioxidant genes controlled by a protein called NRF2. This is unusual: it means a peptide made in mitochondria can influence the cell's main DNA. [83]

Direct binding to CK2, and myostatin

A 2024 study found that MOTS-c binds directly to an enzyme called CK2 and switches it on in muscle but suppresses it in fat. In mice, this was linked to protection from muscle wasting and better sugar uptake by muscle. An earlier study found that MOTS-c lowered blood myostatin, a protein that limits muscle growth, in obese mice; in people, it found only that higher MOTS-c levels went with lower myostatin. [84], [85]

Does it rely on the same machinery as exercise?

A 2026 study in mice found that MOTS-c improved how efficiently muscle mitochondria produced energy, and that the effect depended on PGC-1α and AMPK, two proteins central to how muscle adapts to training. The same paper measured MOTS-c in the leg of exercising men but did not give it to them. [74]

Doserly

Three proposed routes, all from lab studies

Cell and mouse studies, not shown in people

Fuel-gauge switch

Cells; AMPK blockers partly reduced it

1. MOTS-c
2. Slows folate cycle
3. AICAR builds up
4. AMPK switched on
5. More sugar uptake and fat burning

Into the nucleus

Cell study

1. Cell stress
2. MOTS-c moves into nucleus (about 30 min)
3. Works with NRF2
4. Protective and antioxidant genes on

Binding CK2

Cells and mice

1. MOTS-c binds CK2
2. CK2 on in muscle, off in fat
3. Less muscle wasting, more sugar uptake

No receptor for MOTS-c has been identified, according to FDA's 2026 review.

These routes come from cells and mice; none has been shown in people given MOTS-c.

A germ-fighting peptide?

MOTS-c carries a positive charge and a greasy, water-repelling side, like many of the body's natural antibacterial peptides. In a 2026 study it damaged the membranes of E. coli and MRSA (a drug-resistant staph bacterium) in a dish, and bacteria that had been soaked in MOTS-c before being injected into mice no longer caused infection. An earlier mouse study reported better survival from MRSA infection. Neither shows that injecting MOTS-c treats or prevents infections in people. [46], [47]

What did the aging studies in mice find?

The 2021 study behind most longevity claims gave very old mice (starting at 23.5 months of age) MOTS-c three times a week for the rest of their lives. Treated mice had better grip strength, walking and physical capacity in late life. Their median lifespan was 970 days versus 912 for untreated mice, and their maximum 1,120 versus 1,047, but the overall difference was not statistically significant (P = 0.23). The authors wrote that larger groups would be needed. [2]

Doserly

The mouse lifespan result was not significant

One mouse study; no lifespan data in people

Male mice from 23.5 months of age, 15 mg/kg three times a week, injected into the belly cavity for the rest of life

Median lifespan

Untreated 912 days · MOTS-c 970 days (+6.4%)Bars: untreated (light) and MOTS-c (dark), 0 to 1,200 days

Maximum lifespan

Untreated 1,047 days · MOTS-c 1,120 days (+7.0%)Bars: untreated (light) and MOTS-c (dark), 0 to 1,200 days

Overall survival

P = 0.23, not statistically significant

What did improve in the same mice

Grip strength, Walking (gait), Physical capacity in late lifeMeasured in late life; not a lifespan result

The authors wrote that larger groups will be needed. FDA's 2026 briefing and a speaker at FDA's advisory meeting described a lifespan increase.

Treated mice lived about 6% longer at the median, but the difference could easily have been chance.

That nuance was lost as the study was retold. FDA's briefing described the treatment as increasing lifespan, and at the advisory meeting the peptide's discoverer said lifespan increased by 10%. The published figures do not support either statement as a proven effect. [3], [6]

Where the findings are negative or mixed

The positive studies are only part of the record:

• In cells carrying a mitochondrial disease mutation, MOTS-c did not improve energy production. [86]
• At lower laboratory concentrations it did not switch on genes for building new mitochondria; only a very high concentration did. [87]
• In stem cells taken from people with obesity, MOTS-c switched on AMPK but made the cells grow less and show signs of aging, and pretreated cells lost their ability to repair kidneys in mice. [88]
• Swallowed natural MOTS-c did nothing in a mouse colitis model, and injected MOTS-c did not reach the brain well. [66], [67]
• A 2019 paper on bone fracture healing was retracted. [89]

Much of the foundational research also comes from the discoverer's circle: several key papers list authors who consulted for or held shares in CohBar, which licensed MOTS-c. That is disclosed in the papers, and it is a reason independent replication matters. [46], [85], [4]

What are the risks and unanswered questions?

Is MOTS-c safe?

Its safety in people has not been established, and the gap is wider than for most research peptides. FDA found no acute, repeat-dose, genetic-damage, reproductive or cancer studies of MOTS-c in animals, no human data, and no published measurement of how long it stays in the body. Animal papers rarely report side effects at all. [3]

FDA's adverse-event database had no reports for MOTS-c through March 2025. That reflects under-reporting more than safety: FDA notes that pharmacies compounding under the relevant rules generally do not report adverse events, and research-product buyers rarely do. [3]

What side effects have been reported?

The clearest signal is at the injection site. With CB4211, 79% of people had injection-site reactions versus 33% on placebo, and the earlier formulation left persistent bumps beneath the skin. USADA lists increased heart rate or palpitations, injection-site irritation, insomnia, local or generalized immune reactions and fever among side effects reported by people using MOTS-c. [20], [4], [90]

In the public forum threads we reviewed, 79 of the 329 people describing their own use mentioned an injection-site reaction: itchy red welts, hard lumps, burning or bruising lasting from 30 minutes to more than a week, often starting after several doses. Others described fatigue or an afternoon crash (31), appetite changes, usually more hunger (18), trouble sleeping (11), a racing heart (6) and low blood-sugar readings or symptoms (5). One person described dark patches at injection sites. These counts come from self-selected posts, so they are not rates. [22], [91], [35], [40], [92]

Can MOTS-c cause a serious allergic reaction?

Serious allergic-type reactions have been reported, though none has been published as a medical case report. In the threads we reviewed, eight people described whole-body reactions: widespread redness and itching, swollen lips or tongue, tingling in the throat, a racing heart, dizziness or fainting, and in several cases emergency treatment. One person fainted and broke a foot after the second dose of a restarted course. [23], [24], [93], [35], [94]

Two patterns recur. Several reactions came after restarting after a break, or after months of use without problems. And some began with local welts that grew with each dose before a whole-body reaction. At FDA's advisory meeting, a physician member abstained from the vote citing the immunogenicity she sees in her clinic, and an opposing speaker described user reports of hives, heart effects and anaphylaxis. FDA's own concern is that impurities and clumped peptide in injected products can provoke the immune system (immunogenicity). [23], [41], [6], [3]

Swelling of the lips, tongue or throat, trouble breathing, faintness or widespread hives after an injection are signs of a medical emergency.

Can MOTS-c lower blood sugar too far?

It lowered blood sugar in mice, and CB4211 lowered fasting blood sugar by 6% in its small trial. There are no data for MOTS-c in people with diabetes. In forums, a few people describe low readings on a continuous glucose monitor or “sugar crash” symptoms a few hours after 1–3 mg, sometimes while also taking a GLP-1 medicine. Anyone taking insulin or a sulfonylurea (a type of diabetes pill that raises insulin) has a plausible, untested reason for extra care. [39], [21], [61], [27], [34]

Does MOTS-c cause cancer?

Nobody knows. FDA found no carcinogenicity studies, the long-term animal studies designed to detect cancer risk. The evidence points both ways: a mouse study found that MOTS-c slowed ovarian tumors (20 mg per kilogram a day for 30 days), while a 2018 commentary and a 2026 stem-cell study raised the possibility that mitochondrial-derived peptides can push some cells toward an aged, inflammatory state. Neither a cancer risk nor an anti-cancer effect is established in people. [3], [95], [96], [88]

Could product quality change the risk?

Yes. The nominator's certificate of analysis reported 99.2% purity but included no testing for impurities, clumps, bacterial toxins (endotoxin) or microbial contamination, and FDA found that most published certificates for MOTS-c acetate list purity alone. No regulator or university has published an independent analysis of MOTS-c vials sold online. Forum users describe switching sellers to find a product that “worked”, which also means the next vial may not match the last. [3], [41]

Is MOTS-c legal? Is it FDA-approved?

Checked September 24, 2026. Rules differ by country and change quickly. A “research use only” label does not make a product legal to sell or safe to use.

United States. MOTS-c is not an FDA-approved medicine or part of one. The recent steps:

• Earlier. A pharmacy group nominated MOTS-c for pharmacy compounding, then withdrew the nomination. FDA lists it among withdrawn nominations on its page of substances that may pose significant safety risks, noting that no human exposure data exist. Outsourcing pharmacies reported no MOTS-c products from 2017 through 2025. [71], [3]
• May 2026. FDA staff reviewed the free base and acetate on the agency's own initiative and proposed not adding either to the list of bulk ingredients pharmacies may use, citing poor characterization, no safety data and no human studies. [3]
• July 23, 2026. FDA's Pharmacy Compounding Advisory Committee voted 7 to 5, with 2 abstentions, for each form, recommending that they be added. The US Pharmacopeia's representative voted no over how poorly the substance is characterized. This comes from FDA's official livestream; FDA had not posted minutes when we checked. [6], [97]
• September 2026. The vote was advice, not a decision. MOTS-c is not on the official list in federal regulations, and a September 24 search of the Federal Register found no rule naming it. Even if listed, compounded MOTS-c would not be FDA-approved. [98], [97]

Canada. MOTS-c is not authorized. Health Canada's April 2025 advisory about injectable peptides seized from a Calgary clinic lists “Mots-C” among unauthorized products that may pose serious health risks. [99]

Australia. MOTS-c is not a named entry in the June 2026 Poisons Standard, and we found no approval for it. In May 2026 the TGA warned about the risks of importing unapproved peptide products. [100], [101]

New Zealand. Since a Gazette notice of 19 December 2025, “mitochondria-derived peptides and their analogues” are prescription medicines, a group that Medsafe's proposal said includes MOTS-c. [102], [103], [104]

United Kingdom and European Union. We found no authorization and no MOTS-c-specific action by UK or EU medicine regulators in our searches.

Is MOTS-c banned in sport? Does it show up on a drug test?

Yes, it is banned. The World Anti-Doping Agency names MOTS-c on its Prohibited List under S4.4.1, activators of AMPK, prohibited at all times, in and out of competition. It has been named since the 2025 List and remains on the 2026 and 2027 Lists; earlier lists covered it only as a class. USADA says a therapeutic use exemption is “highly unlikely” because MOTS-c has no approved use. [105], [25], [106], [107], [90]

Anti-doping scientists have published a mass-spectrometry test for MOTS-c in blood. How long injected MOTS-c remains detectable has not been published, so any “detection window” quoted online is a guess. A WADA listing also says nothing about whether a substance works. [68]

Who should be especially cautious?

These groups have no safety data in people. That is a reason for caution, not proof of harm.

• Pregnancy and breastfeeding. No reproductive studies exist in animals or people. [3]
• A history of allergies or anaphylaxis. Because of the allergic-type reactions described above. [23], [24]
• Diabetes, especially on insulin or sulfonylureas. Because of the blood-sugar lowering seen in mice and with CB4211. [1], [21]
• A history of cancer. Because long-term cancer studies do not exist. [3]
• Under 18. No studies include young people. This guide is written for adults.
• Competitive athletes. It is banned at all times. [25]

Has MOTS-c been tested alongside other medicines?

Not in people. No study reports how MOTS-c interacts with prescription medicines. In practice it is very often combined with GLP-1-based medicines such as tirzepatide and retatrutide, and with SS-31 and NAD+; in the forum threads we reviewed, 46 of the people describing their own use were also on a GLP-1-type medicine. Those combinations are untested, and they make it impossible to tell which substance caused a change. Bring a complete list of everything you take to a pharmacist or doctor. [3], [34], [108]

What should be monitored while using MOTS-c?

There is no official monitoring plan, because no regulator has approved MOTS-c or written a label for it. What exists is a record of what the CB4211 trial measured and the concerns FDA raised. It can help you prepare questions for a clinician; it is not a personal testing plan. [3]

What did the human trial check?

The CB4211 trial's main measures were adverse events, routine blood tests, vital signs, heart tracings (ECG), physical examinations and injection-site assessments at every stage. It also planned to measure how long CB4211 stayed in the blood and whether people made antibodies against it, but those results were never published. [55]

Which signals matter, and why?

These signals come from an analogue trial and self-selected reports, not from a study of MOTS-c. They show what has been flagged, not what a person will experience. [20], [90], [61]

Can a blood test show my MOTS-c level?

Not reliably. Research tests for MOTS-c disagree with each other by orders of magnitude, a doping laboratory could not confirm one commercial test's results, and there is no accepted normal range. A MOTS-c blood level is a research measurement, not a clinical test. [68]

What do people in public communities report?

Public discussions contain enthusiastic reports, no change at all, and reactions that made people stop, sometimes in the same thread. We reviewed 45 public Reddit threads in full, with 1,497 comments from 329 people describing their own use, plus four other forum threads. Only two of those people said they used MOTS-c on its own. [26], [27]

What do the positive reports look like?

One runner took 3 mg a day for 12 days and cut a 4.3 km run from 24:13 to 20:13, with body fat falling from 15.8% to 14.9%; they had also used other peptides earlier that year and took a stimulant before runs. Another person described a 45-minute ride at a heart rate of 160 feeling like 120. A person with years of chronic fatigue described the least fatigue in seven years, after two courses of SS-31 and alongside NAD+ and several supplements. [38], [41], [36]

These are real experiences. None of them can separate MOTS-c from training, weight loss or the other compounds involved.

Does everyone notice a difference?

No. One person took 1 mg on weekdays for four weeks, then 2 mg for four more, changed sellers, and felt nothing. Another used eight 20 mg vials after a full course of SS-31 and noticed no effect. Others report nothing at 5 mg three times a week, or after eight weeks. [26], [109], [27], [110]

How long does it take, and does it fade?

Reports range from feeling something after the first injection to nothing until week three. A frequent pattern is an early effect that fades: one person felt striking energy after the first two 5 mg doses and felt ill after the third and fourth; another felt good in week one, then had midday crashes in weeks two and three; another said the benefit faded over four months. The accounts cannot give an average time to benefit. [27], [35], [60], [26]

Fatigue, hunger and sleep

Tiredness is the most common unwanted effect after site reactions, especially early on or with daily use. One person had severe fatigue on 2 mg every day but not on 2 mg three times a week. Increased hunger comes up repeatedly, including in people on tirzepatide, one of whom gained 3 lb in a month. Others describe insomnia after a 10 mg morning dose, anxiety that woke them at 3 am, or a resting heart rate in the 140s after 500 mcg, which led them to stop. [26], [40], [111], [110]

What about injection-site reactions?

This is the most consistent theme in both public forums and community education groups. Typical accounts: welts that appear only from week three, last two to three days and come back at each new site; a 4-inch itchy red patch at 5 mg that shrinks to a small spot at 2.5 mg; hives after years of problem-free use that reappeared with a new batch; lumps that grow with each dose until the person stops. [91], [34], [22], [94]

People in community education groups describe the same things: reactions that start at a steady dose after several weeks, get worse after a break or a change of seller, and sometimes spread to other peptides they had tolerated before. Members try many workarounds, including more dilution, different sites, injecting into muscle and taking antihistamines first, with mixed results; several stopped. None of these approaches has been tested, and a worsening local reaction was the first step in some of the whole-body reactions described above. See the allergy section. [112], [113]

What do community education groups teach?

Educators split into two camps: a low, steady approach (about 0.25–1 mg a day or five days a week) and a pulsed approach (3–5 mg two or three times a week, or 10 mg once a week). The most careful course we reviewed says plainly that there is no established human dose and treats 5 mg or more per injection as high risk for reactions. Many courses teach that SS-31 should be started first to “prepare” mitochondria; no study has tested that sequence, and educators now disagree about it.

Some teaching needs correcting. Some lessons claim human trials support 10–20 mg a week (the only human trial used CB4211), give tested athletes a “detection window” (none has been published), or treat the anti-doping ban as proof that MOTS-c works. It is not. [21], [68]

How can you judge a MOTS-c story?

Useful questions: What else started at the same time, especially a GLP-1 medicine, SS-31, NAD+, a new training plan or a diet? How much was injected, per injection and per week, and was the vial's strength confirmed? Did the effect last past the first few weeks? Did the person have any reaction, and what happened on restarting? An explanation of why something happened, such as “folate depletion” or “damaged mitochondria”, is usually guesswork. [35], [39]

These selected discussions help identify questions research should answer. They are not a survey of all users, a response rate or a substitute for controlled studies.

How does MOTS-c compare with humanin, SS-31, NAD+ and 5-Amino-1MQ?

MOTS-c is usually discussed, and often stacked, with other compounds sold for “mitochondrial” energy, metabolism or longevity. The table compares what each one is and how much has been tested in people. Schedules are the ones each compound's own sources describe and cannot be carried over to MOTS-c.

The real differences are in how much has been tested. SS-31 is the only one with an approved medicine, for one rare disease, and some of its larger trials were negative. NAD+ has small randomized trials in specific diseases. MOTS-c, humanin and 5-Amino-1MQ have no human treatment data, although MOTS-c's analogue CB4211 reached a small trial. No study has compared MOTS-c with any of them in people, and the popular idea of starting SS-31 before MOTS-c has never been tested. For tested athletes, MOTS-c is banned by name. [117], [119], [3], [25]

Common questions about MOTS-c

Is MOTS-c the same as CB4211?

No. CB4211 is a modified version of MOTS-c made by the company CohBar, and FDA considers it a different substance. Its 25 mg daily trial dose, its 79% injection-site reaction rate and its effects on liver enzymes belong to CB4211, not to the MOTS-c sold online. The company later judged its formulation unsuitable and wound down. [4], [6] See what the CB4211 trial found.

Has MOTS-c been tested in people?

Not as a treatment. FDA found no clinical studies or human exposure data for MOTS-c by any route. Human studies measure the MOTS-c people already make, for example after exercise, and a 2026 registry entry for a Phase 2 trial is in doubt because the same sponsor filed entries describing themselves as fictional or mock studies. Claims of a “2021 trial in older adults” or human trials supporting 10–20 mg a week trace to no published study. [3], [56], [57] See the human research.

Is MOTS-c “exercise in a bottle”?

No. The nickname comes from mouse studies in which MOTS-c switched on some of the same energy pathways as exercise and helped old mice run farther. Exercise also strengthens the heart, muscles, bones and brain in ways no single signal reproduces, and no human study has shown that injected MOTS-c improves fitness. In people, exercise raises the body's own MOTS-c for a few hours. [2], [1] See how it might work.

Does MOTS-c help with weight loss?

It has not been shown to in people. Mice on a fatty diet gained less weight, but CB4211 produced only a weight “trend” over four weeks, and liver fat fell equally on placebo. Most people reporting weight loss online were also taking a GLP-1 medicine, and several describe more hunger after adding MOTS-c. [1], [21], [40] See weight and blood sugar.

Why does MOTS-c cause itchy welts at the injection site?

Nobody has studied why. Injection-site reactions were the main side effect of CB4211 (79% versus 33% on placebo), and FDA has raised concerns that impurities and clumped peptide in injected products can trigger immune reactions. Forum explanations, such as histamine release, are untested. Welts that spread, keep growing or come with whole-body symptoms are more than a nuisance; some serious reactions started that way. [20], [3], [94] See allergic reactions.

How long does MOTS-c take to work?

There is no evidence-based answer. Personal accounts range from feeling a change after the first injection to nothing after eight weeks, and several describe an early effect that fades within weeks. They cannot give an average time or tell a real effect from a new training plan or another compound. [27], [26], [60] See what people report over time.

Do you need to take SS-31 before MOTS-c?

No study has tested it. Starting SS-31 first to “prepare” the mitochondria is a widespread belief in online and community education groups, and people report good and bad results both ways. SS-31 is an approved medicine only for Barth syndrome, at a labeled dose that cannot be transferred to other uses. [35], [109], [117] See the comparison.

Is it legal to buy MOTS-c?

It depends on where you live, and it is changing. It is not FDA-approved, and an advisory vote for pharmacy compounding has not become a rule; it is unauthorized in Canada and a prescription medicine in New Zealand. A “research use only” label does not make a product legal or safe to use. [6], [99], [102] See the dated legal-status summary.

Glossary

Plain explanations of the route, dosing and research terms used in this guide. Underlined terms in the text link here.

Adverse event

A harmful or unwanted medical event reported after someone used a treatment. A report alone does not prove the treatment caused it.

Aggregation

Peptide molecules clumping together. Clumps can make a product weaker and, when injected, more likely to trigger an immune reaction.

Amino acid

A small chemical building block. Chains of amino acids make up peptides and proteins.

AMPK

An enzyme that acts as the cell's fuel gauge. When energy runs low, it tells the cell to take up more sugar and burn more fat. Exercise switches it on, and so does MOTS-c in cell and mouse studies.

Analogue

A lab-made variant of a molecule with a change to its structure. CB4211 is an analogue of MOTS-c, so its trial results do not apply to MOTS-c itself.

Anaphylaxis

A severe, whole-body allergic reaction that can include swelling of the lips, tongue or throat, trouble breathing, hives and a drop in blood pressure. It is a medical emergency.

Animal study

Research in animals such as rats or mice. It shows what a substance does in a living body, but results in people can differ.

Bioavailability

How much of a dose reaches the bloodstream in a usable form. It depends heavily on the route. For MOTS-c it has not been measured by any route.

Carcinogenicity study

A long-term animal study designed to detect whether a substance can cause cancer. None has been published for MOTS-c.

Cell study (in vitro)

Research on cells grown in a dish. It gives early clues about biology, but it is far from proof of benefit in people.

Compounding

When a pharmacy prepares a customized medicine from individual ingredients. In the US, federal lists control which bulk ingredients pharmacies may use.

Controlled trial

A study that compares people who receive a treatment with a similar group who do not, often receiving a placebo instead. Randomly assigning people to each group makes the comparison fairer.

Course and cycle

A course is the period of repeated use, such as 8 weeks. A cycle is a course plus a planned break before any further use.

Daily total

All the amounts given in one day, added together. For example, 500 mcg twice daily is a 1 mg daily total.

Dose (amount each time)

The amount given on one occasion. A protocol lists both the dose and how often it is given.

Endogenous

Made by the body itself. Most human MOTS-c studies measure endogenous MOTS-c rather than giving it as a treatment.

Endotoxin

A toxic substance from the outer layer of certain bacteria. Injectable products are tested for it because even small amounts can cause fever and inflammation.

Folate cycle

A set of chemical reactions that uses folate (a B vitamin) to help build DNA and other molecules. In cell studies, MOTS-c slowed it, which switched on AMPK.

Free base and acetate

Two forms of the same peptide: on its own (free base) or paired with acetate, a small molecule that helps it dissolve and stay stable. FDA evaluated both forms of MOTS-c.

Half-life

The time it takes for the measured level of a substance in the blood to fall by half. It is not the same as how long an effect lasts. It has not been measured for MOTS-c.

Immunoassay (ELISA)

A lab test that uses antibodies to detect a substance. MOTS-c test kits give very different results from each other and from more specific methods.

Immunogenicity

The ability of a product to provoke an immune response, such as antibodies or an allergic reaction. Impurities and clumps can make injected peptides more immunogenic.

Insulin sensitivity

How strongly the body's cells respond to insulin by taking up sugar from the blood. Better sensitivity means less insulin is needed to control blood sugar.

Intramuscular (IM)

Injected into a muscle.

Intraperitoneal (IP)

Injected into the belly cavity, the space around the abdominal organs. It is the usual route in mouse studies of MOTS-c and is not used in people.

Intravenous (IV)

Given directly into a vein, so it enters the bloodstream immediately.

Investigational

Still being studied and not approved by a regulator, such as the FDA, to treat any condition. MOTS-c itself has not reached human trials.

Freeze-dried (lyophilized)

Dried by freezing and removing the water, leaving a powder. MOTS-c is sold this way and mixed with liquid before injection.

mcg and mg

Micrograms and milligrams. 1 mg equals 1,000 mcg. MOTS-c amounts appear in both, so a missed unit can mean a thousandfold error.

Mitochondrial-derived peptide

A small peptide made from a gene in mitochondrial DNA. Humanin was the first found; MOTS-c is another.

Mitochondria

Tiny structures inside cells that produce most of the cell's energy. They carry a small circle of their own DNA.

Observational study

A study that measures things in people without giving them a treatment, such as comparing blood levels between groups. It can show links but not cause and effect.

Peptide

A short chain of amino acids. MOTS-c is a chain of 16.

Pharmacokinetics

How the body absorbs, moves, breaks down and removes a substance. No such study exists for MOTS-c.

Placebo

A dummy treatment with no active ingredient, used as a comparison in studies.

Preclinical research

Studies done before research in people: cell studies and animal studies.

Reconstitution

Mixing a freeze-dried powder with a liquid so it can be measured and injected. The amount of liquid sets how much peptide each unit holds.

Research use only

A label on products sold for laboratory research. It does not mean a product is approved, tested for human use or legal to sell as a medicine.

Subcutaneous (SC)

Injected into the fatty layer just under the skin. This is the route most MOTS-c protocol descriptions use, though no study has tested it in people.

Syringe units

Markings on an insulin syringe that measure volume. On a U-100 syringe, 100 units equal 1 mL. The amount of peptide per unit depends on the vial's concentration.

Titration

Adjusting a dose in steps, usually starting lower and increasing if needed.

WADA

The World Anti-Doping Agency, which publishes the list of substances banned in sport. MOTS-c is named on it.

Weekly total

All the amounts given in one week, added together. For example, 5 mg three times a week is a 15 mg weekly total.

Withdrawal and rebound

Withdrawal effects are symptoms caused by stopping a substance. A rebound is a problem returning worse than before after stopping. Neither has been studied for MOTS-c.

Explore more of the research

Go deeper into the experiments behind the claims.

Across this guide, the citations include 41 original scientific papers: 22 animal studies, 7 cell studies, 10 studies measuring MOTS-c in people (none gave it to anyone), 2 human trials of related compounds. The optional library below explores 16 of them, grouped by question. Paper counts are not counts of independent research teams: several share authors and methods. Registry records, reviews, websites and personal accounts are counted separately.

In the route details, intraperitoneal means into the belly cavity; intravenous, into a vein; and intracerebroventricular, into the fluid spaces of the brain.

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it: published scientific studies, registered clinical-trial records, regulatory documents, company filings and published protocol descriptions. We also reviewed public online forums and community education groups where people describe their own experiences with MOTS-c.

The guide cites 126 sources, including 41 original scientific papers. Each type of source answers a different question. Studies show what researchers measured. Protocol descriptions show how MOTS-c is typically used. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources